Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain

References 

1. Apple DJ, Solomon KD, Tetz MR, Assia EI, Holland EY, Legler UFC, et al. Posterior capsule opacification. Surv Ophthalmol. 1992;37:73–116
   • Abstract
   • Full-Text PDF (5492 KB)
   • CrossRef
2. Miyake K, Maekubo K, Miyake Y, Nishi O. Pupillary fibrin membrane; a frequent early complication after posterior chamber lens implantation in Japan. Ophthalmology. 1989;96:1228–1233
   • Abstract
3. Wright PL, Wilkinson CP, Balyeat HD, Popham J, Reinke M. Angiographic cystoid macular edema after posterior chamber lens implantation. Arch Ophthalmol. 1988;106:740–744
   • MEDLINE
4. Spaide RF, Yannuzzi LA. Cystoid macular edema after cataract surgery. Semin Ophthalmol. 1993;8:121–129
   • CrossRef
5. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557–634Available at: http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1298410&blobtype=pdfAccessed September 23, 2008
6. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005;5:459–463
   • MEDLINE
7. Price F. Do you welcome BAK? Weighing the toxicity risk. Optometric Management. March 2004;Available at: http://www.optometric.com/article.aspx?article=71020Accessed September 28, 2008
8. Dart J. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease. Eye. 2003;17:886–892
9. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007;18:134–139
   • MEDLINE
10. Kawashima Y, Mitsuaki K, inventors; Santen Pharmaceutical Co, Ltd., assignee. Ophthalmic compositions containing vitamin E or ester thereof as an active ingredient. US patent 5 559 157. September 24, 1996. Available at: http://www.freepatentsonline.com/5559157.html. Accessed September 23, 2008
11. Abelson MB, Washburn S. The downside of tear preservatives. Rev Ophthalmol May. 2002;9:102–104106. Available at: http://www.revophth.com/index.asp?page=1_97.htmAccessed September 23, 2008
12. Schimmer BP, Parker KL. Adrenocorticotropic hormone: adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In:  Hardman JG,  Limbird LE editor. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 10th ed.. New York, NY: McGraw-Hill; 2001;p. 1649–1677
13. Lee HJ, Soliman MRI. Anti-inflammatory steroids without pituitary-adrenal suppression. Science. 1982;215:989–991
    • MEDLINE
14. Lee HJ, Cooperwood JS, You Z, Ko D-H. Prodrug and antedrug: two diametrical approaches in designing safer drugs. Arch Pharm Res. 2002;25:111–136
    • MEDLINE
15. Bikowski J, Pillai R, Shroot B. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol. 2006;5:125–130Available at: http://findarticles.com/p/articles/mi_m0PDG/is_2_5/ai_n16085948Accessed July 10, 2008
16. Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation; for the Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Ophthalmology. 2007;114:1653–1662
    • Abstract
    • Full Text
    • Full-Text PDF (243 KB)
    • CrossRef
17. Duvall B, Kershner RM. Ophthalmic Medications and Pharmacology. 2nd ed.. Thorofare, NJ: SLACK; 2006;53–61
18. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881–1884
    • MEDLINE